- Investing.com
Aurobindo Pharma Limited, a biopharmaceutical company, develops, manufactures, commercializes, and sells generic pharmaceuticals, active pharmaceutical ingredients (APIs), and injectables. The company offers formulation in form of oral solids, liquids, injectables, vaccines, and metered dose inhalers; and APIs, biosimilars, and peptides targeting therapeutic areas, such as central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. It also provides antiretroviral drugs for the people and children living with HIV; and API space for sterile and non-sterile penicillin’s, cephalosporins, penems, and non-beta lactams. The company has operations in India, the United States, Europe, Puerto Rico, and internationally. The company was incorporated in 1986 and is headquartered in Hyderabad, India.
Metrics to compare | ARBN | Peers Peers - average of corresponding metrics from companies closely matching ARBN: CIPLA, HIKAL, MOREPENLAB, LUPIN, EMCURE | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipARBNPeersSector |
---|---|---|---|---|
P/E Ratio | 17.6x | 30.5x | −0.6x | |
PEG Ratio | −5.92 | 0.66 | 0.00 | |
Price/Book | 1.8x | 4.1x | 2.6x | |
Price / LTM Sales | 1.9x | 3.7x | 3.3x | |
Upside (Analyst Target) | 24.9% | 11.6% | 38.7% | |
Fair Value Upside | Unlock | 3.0% | 5.1% | Unlock |